Bhupender Gosain - Pure Bioscience CFO and Corporate Secretary

PUREDelisted Stock  USD 0.13  0.00  0.00%   

CFO

Mr. Bhupender Gosain is Chief Financial Officer and Corporationrationrate Secretary of the Company. 30 years experience in tax and business advisory services in a variety of sectors including technology, life sciences, biotechnology, natural resources and pharma. since 2018.
Tenure 6 years
Phone619 596 8600
Webhttps://www.purebio.com

Pure Bioscience Management Efficiency

The company has return on total asset (ROA) of (0.6231) % which means that it has lost $0.6231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2879) %, meaning that it created substantial loss on money invested by shareholders. Pure Bioscience's management efficiency ratios could be used to measure how well Pure Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 239 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Pure Bioscience has a current ratio of 1.98, which is within standard range for the sector. Debt can assist Pure Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Pure Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pure Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pure to invest in growth at high rates of return. When we think about Pure Bioscience's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

CFO Age

Stephen RobbThe Clorox
51
Stanley SutulaColgate Palmolive
55
Tracey TravisEstee Lauder Companies
62
Dennis HickeyColgate Palmolive
69
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people. Pure Bioscience [PURE] is a Pink Sheet which is traded between brokers as part of OTC trading. Pure Bioscience is listed under Chemicals category by Fama And French industry classification.

Management Performance

Pure Bioscience Leadership Team

Elected by the shareholders, the Pure Bioscience's board of directors comprises two types of representatives: Pure Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pure. The board's role is to monitor Pure Bioscience's management team and ensure that shareholders' interests are well served. Pure Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pure Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Albert Beraldo, Director
Tom Myers, COO
Tom CPA, Pres CEO
Balbir Johal, Director
William Otis, Independent Director
David Pfanzelter, Independent Chairman of the Board
David Theno, Independent Director
Bhupender Gosain, CFO and Corporate Secretary
James Boyce, Director
Dale Okuno, Director
Geoff Balderson, CFO, Director
Henry Lambert, CEO and Director
Thomas Myers, COO Director
Jane Pagel, Director
John Kasperski, VP Sales
Malay Panchal, CEO, Director
Zhinong Yan, Exec Devel
Elisabeth Hagen, Independent Director
Eric Warren, Director
Chandrakant Panchal, Chairman of the Board
Ivan Chen, Independent Director
Tom Lee, Director
Janet Risi, Independent Director
Gary Cohee, Director
Brian ONeill, Director
Mark Elliott, Principal Financial and Accounting Officer and VP of Fin.
Erica Bearss, Independent Director

Pure Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pure Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pure Bioscience using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Consideration for investing in Pure Pink Sheet

If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device